Cytos concentrates on partnerships to conserve cash

Wednesday 3 February 2010

Cytos Biotechnology AG, the Swiss developer of therapeutic vaccines, is focusing its future development work on partnerships with Novartis and Pfizer to conserve cash ahead of the scheduled repayment of its convertible debt in February 2012.

 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland